Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease

Chelsea Caspell-Garcia, Tanya Simuni, Duygu Tosun-Turgut, I. Wei Wu, Yu Zhang, Mike Nalls, Andrew Singleton, Leslie A. Shaw, Ju Hee Kang, John Q. Trojanowski, Andrew Siderowf, Christopher Coffey, Shirley Lasch, Dag Aarsland, David Burn, Lana M. Chahine, Alberto J. Espay, Eric D. Foster, Keith A. Hawkins, Irene LitvanIrene Richard, Daniel Weintraub

Research output: Contribution to journalArticle

57 Scopus citations

Abstract

Objectives To assess the neurobiological substrate of initial cognitive decline in Parkinson's disease (PD) to inform patient management, clinical trial design, and development of treatments. Methods We longitudinally assessed, up to 3 years, 423 newly diagnosed patients with idiopathic PD, untreated at baseline, from 33 international movement disorder centers. Study outcomes were four determinations of cognitive impairment or decline, and biomarker predictors were baseline dopamine transporter (DAT) single photon emission computed tomography (SPECT) scan, structural magnetic resonance imaging (MRI; volume and thickness), diffusion tensor imaging (mean diffusivity and fractional anisotropy), cerebrospinal fluid (CSF; amyloid beta [Aβ], tau and alpha synuclein), and 11 single nucleotide polymorphisms (SNPs) previously associated with PD cognition. Additionally, longitudinal structural MRI and DAT scan data were included. Univariate analyses were run initially, with false discovery rate = 0.2, to select biomarker variables for inclusion in multivariable longitudinal mixedeffect models. Results By year 3, cognitive impairment was diagnosed in 15-38% participants depending on the criteria applied. Biomarkers, some longitudinal, predicting cognitive impairment in multivariable models were: (1) dopamine deficiency (decreased caudate and putamen DAT availability); (2) diffuse, cortical decreased brain volume or thickness (frontal, temporal, parietal, and occipital lobe regions); (3) co-morbid Alzheimer's disease Aβ amyloid pathology (lower CSF Aβ 1-42); and (4) genes (COMT val/val and BDNF val/val genotypes). Conclusions Cognitive impairment in PD increases in frequency 50-200% in the first several years of disease, and is independently predicted by biomarker changes related to nigrostriatal or cortical dopaminergic deficits, global atrophy due to possible widespread effects of neurodegenerative disease, co-morbid Alzheimer's disease plaque pathology, and genetic factors.

Original languageEnglish (US)
Article numbere0175674
JournalPloS one
Volume12
Issue number5
DOIs
StatePublished - May 2017

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease'. Together they form a unique fingerprint.

  • Cite this

    Caspell-Garcia, C., Simuni, T., Tosun-Turgut, D., Wu, I. W., Zhang, Y., Nalls, M., Singleton, A., Shaw, L. A., Kang, J. H., Trojanowski, J. Q., Siderowf, A., Coffey, C., Lasch, S., Aarsland, D., Burn, D., Chahine, L. M., Espay, A. J., Foster, E. D., Hawkins, K. A., ... Weintraub, D. (2017). Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PloS one, 12(5), [e0175674]. https://doi.org/10.1371/journal.pone.0175674